#USA #New York #Securities Fraud #Pomerantz LLP #Simulations Plus

Pomerantz Law Firm's Investigation into Simulations Plus, Inc.

Pomerantz LLP, a renowned law firm specializing in corporate and securities class litigation, has initiated an investigation on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). This investigation arises in light of significant concerns about alleged misconduct involving the company's officers and directors, particularly regarding potential securities fraud and other unlawful business practices. As a leading firm in the field, Pomerantz aims to safeguard the rights of investors who may have suffered losses due to such actions.

Background of the Investigation

The investigation follows the release of Simulations Plus's financial results for the third fiscal quarter, announced on July 14, 2025. The company reported revenues of $20.4 million, falling short of the market consensus estimate of $20.9 million. Moreover, Simulations Plus revealed a staggering net loss of $67.3 million with a diluted loss per share of $3.35. This stark contrast to the previous year’s net income of $3.1 million and earnings per share of $0.15 highlights deepening financial woes.

Adding to investors' concerns, the company disclosed that its dismal performance was partially attributed to a non-cash impairment charge of $77.2 million. In a bid to address these issues, Simulations Plus also revised its adjusted earnings guidance for the fiscal year from a previously anticipated range of $1.07 to $1.20 down to $0.93 to $1.06, indicating further declines in financial expectations.

Restructuring Measures

In June 2025, Simulations Plus had announced the initiation of a restructuring plan aimed at curbing operational inefficiencies and reducing costs. This restructuring included workforce reductions, which were seen as a radical shift for the company, traditionally recognized for its innovative simulation technology in the pharmaceutical sector.

The response from the market was swift; on July 15, 2025, Simulations Plus's stock plummeted by $4.50 per share, representing a dramatic 25.76% decrease, closing at $12.97. This decline underscored the severity of investor sentiment surrounding the company's future.

The Call to Action for Investors

In light of these developments, Pomerantz LLP urges all investors in Simulations Plus to reach out if they believe they have incurred losses as a result of the company's actions or financial disclosures. Investors can contact Danielle Peyton at Pomerantz via email or phone for more information on participating in potential class action litigation.

The firm has a long-standing reputation, having secured numerous multimillion-dollar settlements on behalf of its clients over nearly nine decades in practice, emphasizing its commitment to protecting investors' rights.

Understanding the Implications

As the investigation proceeds, the impact on Simulations Plus and its investors remains to be seen. Investors will be keenly watching the outcomes of both the restructuring efforts and the investigations. The consequences could range from monetary compensation to significant changes in corporate governance and transparency.

Conclusion

The Pomerantz Law Firm’s investigation into Simulations Plus highlights a crucial intersection of corporate accountability and investor rights in the face of disappointing financial disclosures. As stakeholders await further developments, the firm stands ready to champion the interests of affected investors, signaling a potential shift in the dialogue surrounding corporate conduct and responsibility in the tech-driven pharmaceutical simulation industry.